Once weekly interferon β for multiple sclerosis is superseded by higher and more frequent dosing

International Journal of Clinical Practice, Supplement

Volumn , Issue 131, 2002, Pages 9-16

  Blumhardt, L D ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

BRAIN INJURY; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LIVER DYSFUNCTION; MEDICAL PRACTICE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 0036760482     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Alam J, Goelz S, Rioux P et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers. Pharm Res 1997; 14: 546-549.
2. Munafo A, Trinchard-Lugan I, Nguyen TX, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998; 5: 187-193.
3. Runkel L, Meier W, Pepinsky RB et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 1998; 15: 641-649.
4. Goodin DS, Frohman EM, Garmany GP Jr et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178.
5. Khan OA, Tselis AC, Kamholz JA et al. A prospective, open-label treatment trial to compare the effect of Avonex (IFNB-1a), Betaseron (IFNB-1b), and Copaxone (glatiramer acetate) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. J Neurol 2000; 247(Suppl 3): 21.
6. Khan OA, Tselis AC, Kamholz JA et al. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron) and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol 2001; 8: 141-148.
7. Durelli L, Verdun E, Barbero P et al. The Independent Comparison of Interferon (INCOMIN) trial: Final long-term results. Presented at the American Academy of Neurology, 54th Annual Meeting, 13-20 April 2002.
8. Panitch H, Goodin S, Francis G et al. Randomized comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE trial. Neurology 2002; in press.
9. Rothuizen LE, Buclin T, Spertini F et al. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 1999; 99: 131-141.
10. Khan OA, Dhib-Jalbut SS. Serum interferon beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients. Neurology 1998; 51: 738-742.
11. Sturzebecher S, Maibauer R, Heuner A et al. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. J Interferon Cytokine Res 1999; 19: 1257-1264.
12. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145-153.
13. Leppert D, Waubant E, Burk MR et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-852.
14. Miller A, Lanir N, Shapiro S et al. Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases. J Neuroimmunol 1996; 64: 151-161.
15. Lou J, Gasche Y, Zheng L et al. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest 1999; 79: 1015-1025.
16. Rudick RA, Ransohoff RM, Peppler R et al. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis. Ann Neurol 1996; 40: 618-627.
17. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996; 64: 91-100.
18. Abreu SL, Tondreau J, Levine S, Sowinski R. Inhibition of passive localized experimental allergic encephalomyelitis by interferon. Int Arch Allergy Appl Immunol 1983; 72: 30-33.
19. Pozzilli C, Bastianello S, Koudriavtseva T et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: A short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 61: 251-258.
20. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. PRISMS (Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504.
21. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
22. Herndon RM. Treatment of multiple sclerosis with the interferon-betas. BioDrugs 1998; 10: 463-470.
23. Report CPMP/022/98 of the European Agency for Evaluation of Medicinal Products.
24. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636.
25. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995; 45: 1277-1285.
26. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662-667.
27. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655-661.
28. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS study. The Once Weekly Interferon for MS Study Group. Neurology 1999; 53: 679-686.
29. Blumhardt LD. Interferon beta-1a in relapsingremitting multiple sclerosis: A meta-analysis. Neurology 1999; 52(Suppl 2): A498.
30. Biogen Inc. 1995. Summary Basis for Approval. US FDA Official Document for License of Interferon beta-1a (Avonex®). Cambridge, MA; FDA data on file.
31. Clanet M, Kappos L, Radue EW et al. Results of the European interferon beta-1a (Avonex) dose-comparison study. J Neurol 2001; 248(Suppl 2): 63.
32. Khan O, Tselis A, Garbern J et al. A prospective, controlled, open-label trial comparing the effects of Avonex, Betaseron and glatiramer acetate on the relapse rate in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1999; 46: 938.
33. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-399.
34. Trapp BD, Peterson J, Ransohoff RM et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
35. Coles AJ, Wing MG, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
36. De Stefano N, Narayanan S, Matthews PM et al. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999; 122: 1933-1939.
37. Liu C, Edwards S, Gong Q et al. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 66: 323-330.
38. Brex PA, Ciccarelli O, O'Riordan JI et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-164.
39. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419-1428.
40. O'Riordan JI, Thompson AJ, Kingsley DP et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: A 10-year follow-up. Brain 1998; 121: 495-503.
41. Sailer M, O'Riordan JI, Thompson AJ et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999; 52: 599-606.